A5015669893- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Fibroblast Growth Factor Research
- Cytokine Signaling Pathways and Interactions
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Cancer-related Molecular Pathways
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Kruppel-like factors research
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Heat shock proteins research
- Cancer-related gene regulation
- FOXO transcription factor regulation
- PI3K/AKT/mTOR signaling in cancer
- RNA modifications and cancer
- Cancer therapeutics and mechanisms
Hospital Universitario 12 De Octubre
2016-2025
Spanish National Cancer Research Centre
2011-2024
Centro de Investigación del Cáncer
2008-2024
Centro de Investigación Biomédica en Red de Cáncer
2016-2024
Research Institute Hospital 12 de Octubre
2016-2024
Hospital General Universitario De Valencia
2024
Instituto de Salud Carlos III
2017-2023
Centro Nacional de Epidemiología
2018-2022
Medical Research Network
2021
Cancer Research Center
2021
Abstract Paracrine signaling through receptor activator of NF-κB (RANK) pathway mediates the expansion mammary epithelia that occurs during pregnancy, and activation RANK promotes tumorigenesis in mice. In this study we extend these previous data to human cells show development stem breast cancer. Overexpression (FL-RANK) a panel tumoral normal induces expression cancer basal/stem cell markers. High levels untransformed MCF10A induce changes associated with both stemness transformation,...
Abstract Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and associated toxicity have questioned clinical impact of this approach emphasized need alternative treatments. Given limited therapeutic options available these poor understanding molecular mechanisms underlying resistance metastatic lesions to WBRT, we sought uncover actionable targets biomarkers that could help refine patient...
Squamous cell lung cancer (SCC) and adenocarcinoma are the most common histological subtypes of non-small (NSCLC), have been traditionally managed in clinic as a single entity. Increasing evidence, however, illustrates biological diversity these two subgroups cancer, supports need to improve our understanding molecular basis beyond different phenotypes if we aim develop more specific individualized targeted therapy. The purpose this study was identify microRNA (miRNA)-dependent...
Highlights•PDX models mimic the clinical response to docetaxel in breast cancer patients•Sensitivity can be regained metastatic resistant TNBC•A tumor-initiating CD49f chemoresistant population is present TNBC•Docetaxel resistance associates with expansion of a CD49f+ TNBCSummaryTaxanes are mainstay treatment for cancer, but often develops followed by disease and mortality. Aiming reveal mechanisms underlying taxane resistance, we used patient-derived orthoxenografts (PDX). Mimicking...
IntroductionThere is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types cancer, including lung but role this has not been addressed specifically adenocarcinoma.MethodsWe performed FGFR1 and EGFR overexpression co-overexpression assays adenocarcinoma inmortalized cell lines, we also carried out surrogate interaction assays. We monotherapy combination EGFR/FGFR inhibitor sensitivity vitro vivo line– patient-derived xenografts. determined...
Rationale: The characterization of new genetic alterations is essential to assign effective personalized therapies in non-small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers for successful therapies. Molecular YES1, a member the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found significant subset patients with cancer.Objectives: To evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) alteration as therapeutic target...
<h3>Objectives</h3> About a half of patients with frontotemporal dementia (FTD) has deposition phosphorylated TDP-43 protein (pTDP-43) in the brain. We studied pTDP-43 and total levels plasma cerebrospinal fluid (CSF) healthy controls FTD, including those carrying repeat expansion <i>C9orf72</i> gene or mutation <i>GRN</i>. <h3>Methods</h3> included 88 samples 10 carriers, 5 <i>GRN</i> 51 FTD without known 22 controls. also obtained CSF from 25 (2 3 mutation) measured using sandwich ELISA....
Although two growth factor receptors, EGFR and HER2, are amongst the best targets for cancer treatment, no agents targeting HER3, their kinase-defective family member, have so far been approved. Because emergence of resistance lung tumors to kinase inhibitors (EGFRi) associates with compensatory up-regulation HER3 several secreted forms, we anticipated that blocking would prevent resistance. As demonstrated herein, a neutralizing anti-HER3 antibody generated can clear from cell surface, as...
With the idea to discover novel genes involved in proliferation, we have performed a genome-wide loss-of-function genetic screen identify additional putative tumor suppressor genes. We previously identified five belonging different biochemical families. In this report, focused on study of one these designated S-adenosylhomocysteine hydrolase (SAHH), which has also been an independent short hairpin RNA screening. SAHH inactivation confers resistance both p53 and p16(INK4)-induced...
Ectopic expression of conditional murine p53 (p53val135) and oncogenic ras is enough to induce a senescent-like growth arrest at the restrictive temperature. We took advantage this cellular system identify new key players in /p53-induced senescence. Applying retroviral-based genetic screen, we obtained an antisense RNA fragment against PPP1CA, catalytic subunit protein phosphatase 1α, whose loss function bypasses Expression specific short hairpin (sh)RNA PPP1CA impairs p53-dependent...
// Sonia Molina-Pinelo 1, 2, 3 , Ana Salinas 1 Nicolás Moreno-Mata 4 Irene Ferrer Rocío Suarez Eduardo Andrés-León Manuel Rodríguez-Paredes 5, 6 Julian Gutekunst 5 Eloisa Jantus-Lewintre 7, 8 Carlos Camps 9, 10 Amancio Carnero and Luis Paz-Ares Instituto de Biomedicina Sevilla (IBIS) (HUVR, CSIC, Universidad Sevilla), Sevilla, Spain 2 Medical Oncology Department, Hospital Universitario Doce Octubre & Centro Nacional Investigaciones Oncológicas (CNIO), Madrid, CIBER Cáncer, Thoracic Surgery...
EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFRT790M EGFRC797S. It is generally assumed that these mutations render EGFR completely unresponsive to inhibitors, but contrary this, we uncovered here increased STAT3 phosphorylation (p-STAT3) in EGFRC797S tumoral cells. Interestingly, also found concomitant Notch inhibition or treatment induced p-STAT3-dependent strong...
Pathogenic variants in KANSL1 and 17q21.31 microdeletions are causative of Koolen-de Vries syndrome (KdVS), a neurodevelopmental with characteristic facial dysmorphia. Our previous work has shown that syndromic conditions caused by pathogenic epigenetic regulatory genes have identifiable patterns DNA methylation (DNAm) change: DNAm signatures or episignatures. Given the role histone acetylation, we tested whether underlying KdVS associated signature. We profiled whole-blood for 13...
Abstract Drug-tolerance has emerged as one of the major non-genetic adaptive processes driving resistance to targeted therapy (TT) in non-small cell lung cancer (NSCLC). However, kinetics and sequence molecular events governing this response remain poorly understood. Here, we combine real-time monitoring cell-cycle dynamics single-cell RNA sequencing a broad panel oncogenic addiction such EGFR-, ALK-, BRAF- KRAS-mutant NSCLC, treated with their corresponding TT. We identify common path drug...
Lung cancer is the leading cause of death by in world and finding new targets a major medical need to tackle this disease. Here, upon proteomic analysis identify common players oncogenic EGFR- KRAS-driven lung adenocarcinoma mouse models, we uncovered largely unknown protein cancer, flavin-containing monooxygenase 4 (FMO4), whose expression was increased tumors compared with adjacent tissue. FMO4 strongly also samples from patients healthy lung, its level inversely correlated overall...
Abstract Small Cell Lung Cancer (SCLC) is one of the most frequent and deadliest types Cancer, with an overal survival (OS) less than 14 months a 2- year rate not exceeding 7%. Potentially targetable molecular alterations in kinase genes are uncommon SCLC, consequently, treatment has barely changed last fifty years. Irinotecan, Topoisomerase II inhibitor, Lurbinectedin, inhibitor transcription, two only recently approved chemotherapy agents employed as monotherapy second line treatment. Our...
Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays TMB determination differ horizontal coverage, gene content and algorithms, leading to discrepancies results, impacting patient selection. A harmonization study of assessment with available cohort patients NSCLC urgently needed.We evaluated the obtained two marketed next generation sequencing panels: TruSight Oncology 500...